Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide adjunct to insulin in adults with type 1 diabetes
NL-OMON40721Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liraglutide in diabetes mellitus type 1 (T1D) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in glycosylated haemoglobin (HbA1c) after 26 weeks of treatment. Started Jun 2014; status: active, not recruiting.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON40721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40721.